Chlorambucil in indolent chronic lymphocytic leukemia

New England Journal of Medicine

Volumn 338, Issue 21, 1998, Pages 1506-1514

  Dighiero, Guillaume ^a   Maloum, Karim ^b   Desablens, Bernard ^c   Cazin, Bruno ^d   Navarro, Maurice ^e   Leblay, Robert ^f   Leporrier, Michel ^g   Jaubert, Jérome ^h   Lepeu, Gérard ⁱ   Dreyfus, Brigitte ^j   Binet, Jacques Louis ^b   Travade, Philippe ^k   Turpin, François Louis ^l   Tertian, Gérard ^m   Bichoffe, Agnès ⁿ  

^a INSTITUT PASTEUR   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c AMIENS UNIVERSITY HOSPITAL   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e MONTPELLIER UNIVERSITY HOSPITAL   (France)

^f SERVICE DE RHUMATOLOGIE   (France)

^g CAEN UNIVERSITY HOSPITAL   (France)

^h HÔPITAL NORD   (France)

ⁱ CENTRE HOSPITALIER D AVIGNON   (France)

^j University of Poitiers   (France)

^k HÔTEL DIEU   (France)

^l CENTRE RENÉ HUGUENIN   (France)

^m BICÊTRE HOSPITAL   (France)

ⁿ HÔPITAL DU BOCAGE   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; METHOTREXATE; PREDNISONE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHLORAMBUCIL; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MALE; MIDDLE AGED; PREDNISONE; SURVIVAL ANALYSIS;

EID: 0344729013     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199805213382104     Document Type: Article

References (30)

1. Dighiero G, Travade P, Chevret S, et al. B-cell chronic lymphocytic leukemia: present status and future directions. Blood 1991;78:1901-14.
2. Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med 1995;333:1052-7. [Erratum, N Engl J Med 1995;333:1515.]
3. Rai K, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46:219-34.
4. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990-7.
5. International Workshop on Chronic Lymphocytic Leukemia. Chronic lymphocytic leukemia: recommendations for diagnosis, staging, and response criteria. Ann Intern Med 1989;110:236-8.
6. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48:198-206.
7. The French Cooperative Group on Chronic Lymphocytic Leukemia. Effects of chlorambucil and therapeutic decision in initial forms of chronic lymphocytic leukemia (stage A): results of a randomized clinical trial on 612 patients. Blood 1990;75:1414-21.
8. Sawitsky A, Rai KR, Glidewell O, Silver RT. Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia. Blood 1977;50:1049-59.
9. Catovsky D, Richards S, Fooks J, Hamblin TJ. CLL trials in the United Kingdom: MRC trials 1, 2 and 3. Leuk Lymphoma 1991;5:Suppl 4:105-11.
10. Shustik C, Mick R, Silver R, Sawitsky A, Rai K, Shapiro L. Treatment of early chronic lymphocytic leukemia: intermittent chlorambucil versus observation. Hematol Oncol 1988;6:7-12.
11. Begleiter A, Mowat M, Israels LG, Johnston JB. Chlorambucil in chronic lymphocytic leukemia: mechanisms of action. Leuk Lymphoma 1996;23:187-201.
12. Jaksic B, Brugiatelli M. High dose continuous chlorambucil vs intermittent chlorambucil plus prednisone for treatment of B-CLL - IGCI CLL-01 trial. Nouv Rev Fr Hematol 1988;30:437-42.
13. Jaksic B, Brugiatelli M, Krc I, et al. High dose chlorambucil versus Binet's modified cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia: results of an international multicenter randomized trial: International Society of Chemo-Immunotherapy, Vienna. Cancer 1997;79:2107-14.
14. Dighiero G, Binet JL. Chronic lymphocytic leukemia. Hematol Cell Ther 1996;38:Suppl 2:S41-S63.
15. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
16. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc [A] 1972;135:185-206.
17. Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972;34: 187-202.
18. Pocock SJ. Group sequential methods in the design and analysis of clinical trials. Biometrika 1977;64:191-9.
19. The French Cooperative Group on Chronic Lymphocytic Leukaemia. Natural history of stage A chronic lymphocytic leukaemia untreated patients. Br J Haematol 1990;76:45-57.
20. Idem. A randomized clinical trial of chlorambucil versus COP in stage B chronic lymphocytic leukemia. Blood 1990;75:1422-5.
21. Idem. Is the CHOP regimen a good treatment for advanced CLL? Results from two randomized clinical trials. Leuk Lymphoma 1994;13:449-56.
22. Catovsky D, Fooks J, Richards S. The UK Medical Research Council CLL trials 1 and 2. Nouv Rev Fr Hematol 1988;30:423-7.
23. Berk PD, Goldberg JD, Silverstein MN, et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med 1981;304:441-7.
24. Kauppi MJ, Savolainen HA, Anttila VJ, Isomaki HA. Increased risk of leukaemia in patients with juvenile chronic arthritis treated with chlorambucil. Acta Paediatr 1996;85:248-50.
25. Dedrick RL, Morrison PF. Carcinogenic potency of alkylating agents in rodents and humans. Cancer Res 1992;52:2464-7.
26. Patapanian H, Graham S, Sambrook PN, et al. The oncogenicity of chlorambucil in rheumatoid arthritis. Br J Rheumatol 1988;27:44-7.
27. Palmer RG, Denman AM. Malignancies induced by chlorambucil. Cancer Treat Rev 1984;11:121-9.
28. Keating MJ, Kantarjian H, Talpaz M, et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 1989;74: 19-25.
29. Johnson S, Smith AG, Löffler H, et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. Lancet 1996;347:1432-8.
30. Rai KR, Peterson B, Elias L, et al. A randomized comparison of Fludarabine and Chlorambucil for patients with previously untreated chronic lymphocytic leukemia: a CALGB, SWOG, CTG/NCI-C and ECOG Inter-Group study. Blood 1996;88:Suppl 1:141a. abstract.